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Tumor necrosis factor alpha antagonists (TNFA) are biological agents to treat chronic
inflammatory and autoimmune diseases. However, their use is associated with an increased
rate of tuberculosis, endemic mycoses, and intracellular bacterial infections. Since tuberculosis
is moderately to highly endemic in Colombia, the risk of these infections in patients treated with
TNFAs may be higher than previously reported in Colombia. Recently, four patients have
developed tuberculosis during TNFA therapy. Tuberculosis appeared between 3 to 24 months
after initiation of TFNA therapy and was independent of previous tuberculin skin test status. A
review of the relevant literature and recommendations are presented as guides for surveillance
and prophylaxis on a country-wide basis.
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Tuberculosis en pacientes tratados con antagonistas del factor de necrosis tumoral alfa
en un área endémica, ¿vale la pena el riesgo?
Los antagonistas del factor de necrosis tumoral alfa (infliximab, adalimumab y etanercept)
son agentes biológicos utilizados en el tratamiento de enfermedades inflamatorias crónicas
y autoinmunes. Sin embargo, su uso está asociado con el incremento de la tasa de
tuberculosis, micosis endémicas e infecciones bacterianas intracelulares. Dado que la
tuberculosis es moderada/altamente endémica en Colombia, el riesgo de esta infección en
los pacientes tratados con estos agentes biológicos puede incrementarse y hacer dicha tasa
mayor que la informada previamente (tanto en Colombia como en el mundo). Se presentan
cuatro pacientes que desarrollaron tuberculosis durante el tratamiento con antagonistas del
factor de necrosis tumoral alfa. La presentación de la tuberculosis ocurrió en promedio 15
meses después del inicio del agente biológico y fue independiente de la prueba de tuberculina.
Se hace una revisión del tema y se plantea la necesidad de implementar guías y estrategias
gubernamentales orientadas a la detección y profilaxis de tuberculosis en este grupo de
pacientes.
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Tumor necrosis factor (TNF)-alpha antagonists
(infliximab, adalimumab and etanercept) are
biological agents designed to treat inflammatory
and autoimmune diseases including rheumatoid
arthritis (RA), ankylosing spondylitis (AS),
psoriasis and Crohn’s disease, as TNF-alpha, a
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cytokine, plays an essential pathogenic role in
these diseases (1-3). Patients with these disorders
are unresponsive to conventional immuno-
modulatory treatment; however, dramatic
improvement has been demonstrated with the use
of the TNF-alpha antagonist therapy. This use is
associated with an increased rate of tuberculosis
(TB), endemic mycoses, and intracellular bacterial
infections (4). Since TB is moderately to highly
endemic in Colombia, the risk of these infections
in patients treated with these agents are predicted
to be higher than previously reported elsewhere.
Herein, four patients are presented who developed
TB during TNF-alpha antagonist therapy. The
relevant literature is reviewed, and guidelines for
surveillance and prophylaxis are proposed. These
patients were seen at the Unidad de Inmunología
Clínica y Reumatología in the Clinica Universitaria
Bolivariana, a third level clinic, in Medellin,
Colombia. The total number of patients with RA
seen in the Unit was approximately 440 out-
patients, of whom 66 (15%) were under TNF-alpha
antagonist therapy.
Case description (table 1)
Case 1
A 33-year-old female patient, with a history of
ankylosing spondylitis (AS) of one year’s dura-
tion and a recurring chronic anterior uveitis was
treated successfully for both with prednisone (60
mg/day) and methotrexate at 15 mg intramuscu-
lar (IM) per week. She was then initiated on
infliximab at 200 mg intravenous (IV) every 8 weeks
and achieved complete recovery of her uveitis and
of the Inflammatory back and axial pain.
After three months on infliximab therapy, she was
admitted to the Rheumatology Unit of Bolivarian
University Clinic (Medellín, Colombia) due to a 15-
day condition consisting of a painful, developing
cervical mass and of dysphagia that had not re-
sponded to oral treatment with antibiotics.
On physical examination, her temperature was
36.8°C, blood pressure 110/70 mm Hg, heart rate
70 beats per minute and respiratory rate 18 breaths
per minute. In the right cervical region, a 3 cm
diam erythematous adenopathy was found-it was
hard, deeply rooted and painful. The examination
was otherwise normal. Presumptive evidence for
reactive syphilis was found in laboratory exami-
nations, albeit at low titers; this was later con-
firmed by a FTA-ABS test. Neurosyphilis was ruled
out by lumbar puncture results. Test for human
immunodeficiency virus (HIV) infection (by Axsym
assays, Abbott Laboratories, Chicago, USA) was
negative. Blood count, coagulation tests, renal and
liver function tests were within the normal range.
A significant increase in reactive C protein (9.8
mg/dl, VN: 0-1) was noted. Chest X-ray was nor-
mal and cervical tomography showed a conglom-
erate of cervical adenopathies in the right jugular
groove. A fine-needle aspiration biopsy on the
palpable adenopathy showed lymphocytic hyper-
plasia. The biopsy by excision was compatible
with chronic caseous granulomatous inflammation
(figure 1). Stains for acid-fast bacilli (Ziehl Nielsen)
and for fungus (methenamine silver) were nega-
tive, but later Mycobacterium cultures proved posi-
tive for M. tuberculosis.
The patient was sent to the public health
tuberculosis program for approppiate treatment.
The immunosuppressant therapy was not
reinitiated, given that her clinical uveitis had gone
into complete remission and articular symptoms
were absent.
Case 2
A 47-year-old male was given a diagnosis of AS
of three years duration. He had no clinical response
to methotrexate treatment at 15 mg IM per week
and indomethacin at 150 mg/day. Therefore,
infliximab was initiated at 200 mg IV every 8
weeks. The patient had a negative tuberculin skin
test (TST) done three months before starting treat-
ment with infliximab.
He was admitted to our Rheumatology Unit with a
history of excessive bowel movements, and mu-
cus diarrhea, fever, nocturnal diaphoresis, facial
swelling, loss of appetite and weight loss of 7 kg
in 20 days. Physical examination indicated a tem-
perature of 37.5 °C, blood pressure of 120/80 mm
Hg, heart rate of 100 beats per min and respira-
tory rate of 16 breaths per min. Abdominal palpa-
tion produced pain, without peritoneal irritational
signs. The remainder of the physical examination
was normal.
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Laboratory tests showed a significant increase in
lactic dehydrogenase (1,398 units/ml. VN: 313-
618) and in C reactive protein (11 mg/dl, VN: 0-1).
Hematologic laboratory values showed only a
slight thrombocytosis (507,000 cells/µl, VN:
150,000-450,000). The results of liver and renal
function tests, and the levels of serum electro-
lytes were within the normal range. Stool tests
were normal. He tested negative for HIV.
Chest X-ray showed alveolar infiltrates in the lower
left lobe and a small pleural effusion. An abdomi-
nal sonography revealed splenomegaly and free
liquid in the cavity making possible a needle-guided
paracentesis. Ascitic fluid was obtained which
showed pH: 7.56, albumin: 2.0 g per dl, white-cell
count of 3,040 cells/µl, 95% of which were lym-
phocytes. The albumin gradient was 1.3 mg/dl.
The cultures were negative for aerobic bacteria,
fungi, or mycobacteria. An upper gastrointestinal
endoscopy and a colonoscopy failed to reveal
pathologic changes. Consequently, an abdominal
computerized axial tomography was done, in which
an increase in fat density and adenomegalies were
observed at the root of the mesentery. In order to
rule out a neoplastic or granulomatous disease, a
guided laparoscopic peritoneal biopsy was done.
This procedure revealed a chronic caseous granu-
lomatous inflammation (figure 2) and the biopsy
was positive for acid-fast bacilli (AFB). Anti-TB
treatment was initiated. The patient was dis-
charged, but continued treatment under the pub-
lic health TB program. The infliximab treatment
was suspended.
Case 3
A 45-year-old female patient was presented with
a 14 years history of RA. She recently had been
treated with prednisone at 15 mg/day, naproxen
at 500 mg twice a day, methotrexate at 15 mg PO
per week, and chloroquinine at 250 mg/day PO.
Previously, intolerance to sulfasalazine had been
recorded. Despite this regimen of treatment, she
persisted with a high articular index (>10). Due to
the refractory nature of the disease, treatment with
infliximab was started at 200 mg IV every eight
weeks. She received this treatment for ten months
with an excellent clinical response (ACR70).
Figure 2. Confluent peritoneal caseous granulomatous
inflammation, HE, 10X.
Figure 1.  Granulomatous lesions with caseous necrosis
and disruption of the granuloma formation, HE, 40X.
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During the follow up, she presented a month-long
febrile condition with tachycardia, migraine head-
aches and lumbar pain. In addition, left knee effu-
sion and arthralgia of the wrists and left elbow
was detected. She was then admitted to the Rheu-
matology Unit as an in-patient for studies of pro-
longed febrile syndrome. On admission, she de-
nied respiratory symptoms. A left knee arthrocen-
tesis was done, ruling out pyogenic arthritis.
Laboratory testing showed lymphopenia (770 cells/
µl, VN: 900-5000) and a significant increase in C
reactive protein (7.7 mg/dl) and sedimentation rate
(70 mm/h). Liver and renal function tests were
within the normal ranges. She tested negative for
HIV, fungi, and cytomegalovirus infection. Syn-
ovial fluid smear, blood cultures for aerobic bac-
teria, fungi and Mycobacterium were negative.
An abdominal sonography revealed splenomegaly.
Chest x-ray showed a range of sizes of poorly
defined, bilateral alveolar opacities, situated mainly
in the upper lobes, along with liquid in the posterior
pleural cavity (figure 3A). A high resolution com-
puted tomography of the thorax (figure 3B) showed
poorly defined pulmonary nodules with spiculated
lesions, between 2 mm and 1 cm in size, and sur-
rounding pneumonitis mainly located in the upper
lobes. In addition, interstitial lesions were seen
as well as enlargement of the posterior pleural and
multiple small, irregular, peripheral nodules.
A fiberoptic bronchoscopy was performed to ob-
tain a bronchoalveolar lavage (BAL) and a
transbronchial biopsy. The latter was insufficient
for an adequate analysis, but BAL was positive
for acid-fast bacilli (AFB) and M. tuberculosis grew
in the cultures. Anti-TB treatment was initiated.
Infliximab was suspended and methotrexate tem-
porarily suspended, given the low autoimmune dis-
ease activity, and to avoid the hepatotoxicity of
the association with isoniazid. She was released
to continue treatment on an outpatient basis.
Case 4
A 72-year-old female patient was presented with
a two-month history of dyspnea, cough, and tho-
racic pain. She was under treatment with digoxin,
metoprolol, enalapril, furosemide and spironolac-
tone for arterial hypertension, auricular fibrillation
and left ventricular hypertrophy. In addition, she
had a three-year history of RA, treated for the last
two years with adalimumab (previous use of meth-
otrexate and low dose steroids were considered
inadequate).
Chest x-rays showed alveolar infiltrates and central
calcified granulomas. A computed tomography
scan of the paranasal cavities showed chronic
sinusitis. A fungal diagnosis was ruled out by
biopsy and appropriate smears. The patient
received treatment with levofloxacine.
One month later, she was readmitted due to
auricular fibrillation with a rapid ventricular reaction
and fever. She was treated with cefepime and
amikacin because of a suspicion of partially treated
Figure 3. (A) Chest X-ray showing different sizes of poorly defined, bilateral alveolar opacities mainly involving the upper
lobes with associated pleural effusion. (B) A thorax high resolution computed tomography showing poorly defined nodules
with spiculated lesions (arrow), between 2 mm and 1 cm in size, with pneumonitis surrounding the area (head arrow) and
enlargement of the posterior pleura.
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pneumonia. A slight pericardial effusion was found
in a transthoracic echocardiogram, and pulmonary
thromboembolism was confirmed by a ventilation-
perfusion scintigraphy. Anticoagulation was given
and she was released with oral antibiotics.
She was readmitted two weeks later because of a
sudden episode of dyspnea, asthenia, adynamia,
fever and diaphoresis. High sedimentation rate (62
mm/h) and C-reactive protein (13 mg/dl) were
found, accompanied by normocytic and
normochromic anemia (10.1 g/dl) and negative
blood cultures for bacteria. An increased heart size
on a chest radiograph was recorded. A new
echocardiogram showed an increase of pericardial
effusion. Thickening and pericardial effusion, medias-
tinal adenopathies and a calcified granuloma in
the lower left lobe were observed in a high resolution
thorax computed tomography (figure 4). A
pericardial biopsy was taken that disclosed
caseous necrosis and AFB in the Ziehl Nielsen
stain. Treatment for pericardial TB was started.
The patient developed lymphopenia (438 cells/µl,
VN: 1,000-5,000). Prednisone treatment at 60 mg/
day was initiated, and a few days later the patient
was released to continue treatment under the
public health TB program. Adalimumab was
suspended.
Discussion
Tuberculosis is a serious disease in Colombia.
Its rapid growth is encouraged by poor social-
economic conditions, the low quality of the public
health programs and, recently, by the HIV
epidemic. At present, a new population of patients
is being threatened. As a result of recent advances
in the medical sciences, the new TNF-alpha
antagonists are revolutionizing treatment for
patients with chronic inflammatory and autoimmune
diseases and noticeably improving the state of
their health and quality of life. Nevertheless, such
treatment has side effects, one of the most
troubling is the reactivation of TB. Here, four
patients are presented who developed severe TB
disease during TNF- alpha antagonist therapy. The
bases of the problem are reviewed and the status
of the current situation is summarized.
TNF alpha and inflammation
TNF-alpha is a cytokine that plays a critical role
in the regulation of inflammatory processes and
takes a part in apoptosis, cell activation, cell re-
cruitment and differentiation. It is produced prima-
rily by macrophages in response to stimuli acti-
vating toll-like receptors, but can also be ex-
pressed by activated T cells, B cells, and NK cells
Figure 4. Thorax high resolution
computed tomography showing
pericardial thickening and effusion.
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(5). This cytokine has a role in septic shock and
acute respiratory distress syndrome (ARDS); in
addition, it has been implicated in the pathogen-
esis of chronic processes such as autoimmunity,
graft-versus-host disease, Crohn’s disease, and
cachexia accompanying cancer, as well as the
acquired immunodeficiency syndrome. TNF has
also been implicated in insulin resistance, endot-
helial activation, congestive heart failure, athero-
sclerosis, pancreatitis, and alcohol-induced liver
injury, among others (6,7).
TNF alpha is present at biologically significant
levels in RA synovial tissue and fluid. Furthermore,
the level of TNF alpha in the synovium seems to
parallel the extent of both inflammation and bone
erosion. TNF triggers several of the most central
and critical events in the acute and chronic syn-
ovial inflammation, as well as the ultimate tissue
destruction characteristic of RA, including induc-
tion of multiple additional cytokines and chemokines,
expression of adhesion molecules and synovial
neoangiogenesis (8). TNF alpha is highly ex-
pressed at the site of inflammation in AS-although
it does not seem to be elevated systemically, but
rather, highly expressed locally at the primary site
of inflammation, such as the sacroiliac joint (9).
TNF-alpha and TB
TNF-alpha is an essential component in the pro-
cesses leading to an effective host response
against TB. It is necessary for optimal coordination
of the two aspects of TB immunity: (1) the adequate
differentiation of specific T cells to secrete an
appropriate Th1 cytokine profile and (2) the devel-
opment of granulomas in which activated epithe-
lioid macrophages restrict mycobacterial growth
and dissemination (5). A synergistic activity oc-
curs between interferon (IFN) gamma, one of the
central mediator of Th1 type response, and TNF-
alpha in the activation of macrophages. The acti-
vation induces macrophage differentiation into epi-
thelioid cells and increases their phagocytic ca-
pacity (10,11).
The formation of granulomas at the site of myco-
bacterial infection is an essential component of
host immunity designed to control infection. This
process is dependent on the activation of myco-
bacteria-reactive T lymphocytes, particularly IFN
-secreting CD4 and CD8 T cells. Granuloma for-
mation, however, is a complex process that re-
quires not only the activation of the lymphocytes,
but also their recruitment with monocytes to the
site of the infection, migration into the tissues,
and juxtaposition around mycobacteria-infected
macrophages (12). TNF alpha is required for the
early induction of chemokines that initiates timely
cell recruitment as well as the establishment and
maintenance of the microenvironment in the pro-
tective granulomas (12).
In the absence of TNF-alpha, the granuloma be-
comes disorganized and diffuse, with the devel-
opment of caseous lesions and an incapacity to
contain the bacteria (a sign of the disruption of
the protecting mechanism) and concomitant dis-
semination of the infection (5,10). The importance
of this cytokine in the expression of the HIV me-
diated by nuclear factor kappa beta during co-in-
fection with TB is also known (13,14).
TNF-alpha antagonists
Three TNF-alpha antagonists for the treatment of
RA (infliximab, adalimumab and etanercept) have
been approved in the last several years. Infliximab
has been approved also for the treatment of pso-
riatic arthritis (PsA) and Crohn’s disease, and
etanercept for the treatment of PsA.
Etanercept is a soluble TNF-receptor fusion pro-
tein and is composed of two dimers. Each has an
extracellular, ligand-binding portion of the higher-
affinity type 2 TNF receptor (p75) linked to the Fc
portion of human IgG1 (15). Infliximab is a chi-
meric monoclonal antibody (murine-binding VK and
VH domains, with human constant Fc domains)
that combines with TNF-alpha with great affinity
and thereby impairs the binding of TNF alpha to
its receptors. It also kills cells that express TNF
alpha through antibody- dependent and comple-
ment-dependent cytotoxicity (16). Adalimumab,
the latest TNF-alpha antagonist, is a recombinant
monoclonal antibody that binds TNF-alpha and also
causes lymphocyte apoptosis and rupture of the
cells that express TNF-alpha on their surface (17).
The value of TNF-alpha antagonist therapy in RA
is its ability to (a) decrease the acute phase reac-
tants in serum, (b) reduce lymphocyte infiltration
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in the synovium, (c) inhibit the cascade of
proinflamatory cytokines, (d) deactivate the en-
dothelium, modulate chemotaxis at the sinovium
level (18) and (e) decrease levels of soluble leu-
kocyte-endothelial  adhesion molecules (IL-1 and
IL-6) at the systemic level. Multiple studies have
shown that these medications given either as
single-therapy or as combined-therapy allow a
rapid, significant, and sustained clinical improve-
ment, as well as a decrease in the radiological
progression of RA.
The effectiveness of TNF-alpha antagonist therapy
has also been demonstrated for Crohn’s disease
(19), PsA (20), AS (9), some types of vasculitis
(21) and uveitis (22). Variable success has been
reported for sarcoidosis (23) and it has proven an
unsuccessful treatment in Sjogren’s syndrome
(24,25), as well as an association with moderate
to severe chronic heart failure (26).
TNF-alpha antagonists and TB
Since the introduction of TNF-alpha antagonists,
an increase in the cases of TB within the treated
population has been observed. In the United
States. TB rates have increased from 6.2 per
100,000 in the general population to 144 per
100,000 in patients who are receiving treatment
with infliximab and 35 per 100,000 in those who
receive etanercept (27). In Spain, the estimated
incidence of TB associated with infliximab in RA
patients was 1,893 per 100,000 in the year 2000,
compared with a previous incidence of 21 per
100,000 in the general population and 95 per
100,000 among RA patients not exposed to TNF-
alpha antagonist therapy (28). A world rate of 47.6
per 100,000 for infliximab and 20.7 per 100,000
for etanercept has been calculated (29). Soluble
TNF-alpha mainly interacts with TNFR1 (TNF-al-
pha receptor), while membrane-bound TNF-alpha
exerts its actions via TNFR2. TNFR1 is essential
for both granuloma formation and containment of
intracellular pathogens, whereas TNFR2 plays a
less significant role (4). This difference partially
explains the varying infectious risk between
infliximab and etanercept, and is in accord with
the observation that infliximab is more useful than
etanercept in treating granulomatous diseases
such as Crohn’s disease and sarcoidosis (4).
Quite probably, the majority of the TB cases in-
duced by the use of TNF-alpha antagonist repre-
sent reactivation of a latent condition. Usually,
reactivation occurs within the first two to five
months, corresponding to three doses of treatment
(30), although this complication has been reported
to occur up to 20 months after treatment with
etanercept. In our series, we observed three TB
cases under infliximab treatment; they appeared
within a time interval between the first dose and
the TB diagnosis of three to ten months. With
adalimumab, this occurred after 24 months of treat-
ment. In some studies, the majority of the pa-
tients came from countries with a low incidence
of TB, such as the United States and Europe
(28,30). Nevertheless, eight to twelve of the pa-
tients reported in the state of California (United
States) between 2002 and 2003 were originally
from countries where TB is prevalent (31).
The disease manifestations in this group of pa-
tients has been shown to be similar to that of other
immunosuppressed patients, with the majority be-
ing extrapulmonary  forms (56%-65%) and sev-
eral disseminated forms (24%); mortality rates are
between 5%-11% (28,30). The unusual manifes-
tations induced by the TNF-alpha antagonist pos-
sibly accounts for the delay in diagnosis of TB,
since these delays occur in cases of pulmonary
TB in patients with RA and ileocaecal TB in pa-
tients with Crohn’s disease. For these cases, ac-
curate diagnosis may be difficult because of the
inability to differentiate degree of pulmonary in-
volvement in the RA cases and TB from Chrohn’s
relapse in the latter cases (32,33). The main clini-
cal manifestation of disease in our series was
extrapulmonary, and consisted of two cases with
infliximab (cervical and abdominal lymphadenopa-
thy) and one case with adalimumab (pericardial).
The other patient, who was treated with infliximab,
had a pulmonary manifestation of TB disease
(table 1).
A series of recommendations for TB screening
and treatment of latent infection and active TB in
those patients have been generated. The Centers
for Disease Control in Atlanta (United States) has
recommended the following, complete checklist
of risk factors for M. tuberculosis infection in all
patients before initiating TNF-alpha antagonists:
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(a) birth in a country where TB is prevalent or (b)
history residence in a congregate setting (e.g.,
jail or prison, homeless shelter, or chronic-care
facility), (c) a positive  tuberculin skin test (TST)
result, (d) substance abuse (injection or other-
wise), (e) health-care employment in settings with
TB patients, and (f) chest radiographic findings
consistent with previous TB (31).
Application of the Purified protein derivative (PPD)
TST is the only widely used method to detect la-
tent tuberculosis infection (LTBI) and is depen-
dent on a normal T cell function. In RA, the T cell
function is altered and may result in an inability to
develop an adequate PPD reaction. Several au-
thors have demonstrated that a PPD skin test is
not appropriate for recognizing LTBI in patients with
RA in a specific population (34).
Although false-positive results can occur in
countries where BCG vaccine is given after
infancy, Gardam et al (29) have recommended a
conservative approach in the setting of TNF alpha
antagonists, whether or not BCG vaccination was
the cause of a positive skin test. They also
recommend that patients who are to start an
immunosuppressive therapy or who have impaired
immunity due to illness should undergo TST before
therapy or as soon as possible after the diagnosis
of the immunosuppressive disease. The will keep
to a minimum the risk of false-negative reactions
due to anergy (29).
Treatment for LTBI should be initiated for immu-
nosuppressed patients with a TST result of >5
mm and/or chest radiograph findings suggestive
of past TB. This treatment is also recommended
for patients with a negative TST in whom the clini-
cal and epidemiological circumstances suggest
M. tuberculosis infection. The treatment sug-
gested by the Centers for Disease Control and
the Spanish Rheumatology Society (35) is iso-
niazid at 300 mg per day for nine months. In some
highly endemic countries, a six month treatment
with LTBI is recommended (36). The time for initi-
ating biological therapy has not been defined but
it is preferable to start it once the treatment with
INH has been completed. In any case, TNF-alpha
antagonist must not be the first step in treatment.
Preferably TNF-alpha antagonist therapy should
is not to be initiated during INH prophylaxis, since
patients can develop TB under this treatment (37).
Recommendations based on the treatment of LTBI
in patients with HIV indicate that it is not neces-
sary to continue treatment with isoniazid even if
the immunosuppressant treatment has to continue
for a long time (38). Liver toxicity caused by iso-
Table 1. Characteristics of patients with tuberculosis under treatment with TNF-alpha antagonists.
Case 1 Case 2 Case 3 Case 4
Age 33 47 45 72
Sex Female Male Female Female
Diagnostic AS AS RA RA
Time of disease 1 year 3 years 14 years 3 years
progression
Previous treatment Methotrexate, Methotrexate Methotrexate, NSAID,
steroids  chloroquinine, steroids Steroids
Previous TB No No No No
Previous BCG Yes Yes Yes Yes
Tuberculin test Negative Negative No No
Previous history of TB contact Unknown Unknown Yes No
TNF-alpha antagonist Infliximab Infliximab Infliximab Adalimumab
Interval between first dose 3 months 24 months 9 months 24 months
and diagnosis
Clinical manifestation of disease Ganglionar Peritoneal Pulmonary Pericardial
AS: ankylosing spondylitis RA: rheumatoid arthritis, NSAID: non-steroidal anti-inflammatory drugs
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niazid may be enhanced in these patients, prob-
ably due to concomitant treatment with other
drugs such as methotrexate and NSAIDs (non ste-
roidal anti-Inflammatory drugs).The combination
use of pyrazinamide and rifampicin has not been
recommended due to the excessive risk of
hepatotoxicicity.
It has been demonstrated that strategies to treat
LTBI that are tailored to the at-risk population can
effectively and safely lessen the likelihood of ac-
tive TB in patients treated with TNF-alpha antago-
nist therapy, decreasing the TB rate by 78% (35).
Noteworthy, TB disease can occur despite the
above recommendations for the treatment of LTBI.
This is not very surprising, since the evidence
indicates that 9 months of treatment with isoniazid
does not fully protect against the development of
active TB.  Although the decrease in the rate is ~70%,
this figure rises to approximately 90% in patients
who are compliant with the medication (39).
Active TB must always be considered a potential
cause of febrile or respiratory disease in patients
who are receiving TNF-alpha antagonist therapy.
Because it blocks of the cytokine activity, mani-
festations of TB disease in this group of patients
may be more subtle. Chest X-ray and sputum cul-
tures are recommended in all cases (32).
The British Thoracic Society guidelines
recommend that a full course of standard anti-TB
therapy be completed prior to the initiation of TNF-
alpha antagonist therapy if the patient is found to
have active TB. However, under some
circumstances, it can be initiated in consultation
with other specialists caring for TB patients (40).
Treatment for TB is to be given for at least 2
months (with full compliance), or until the drug
susceptibility profile of the organism is known, prior
to commencing TNF-alpha antagonist therapy (40).
If active TB is found during TNF-alpha antagonist
therapy, the treatment must be adjusted to that
defined by the TB program; furthermore the TNF-
alpha antagonist therapy must be suspended at
least until anti-TB treatment has been initiated and
the patient’s condition has improved (31). However,
some professionals recommend the resumption
of TNF-alpha antagonist therapy be avoided in
patients who had developed TB under its use (41).
Table 2 summarizes expert panel committees
Table 2. Summary of main recommendations (expert panel committees) for the prevention and treatment of tuberculosis




Symptoms inquiry and clinical examination
Search for risk factors
– Indications of prophylaxis
Patients with positive tuberculin skin  test (>5mm)
     Option: If  tuberculin test is unreliable this should not be performed and patients are to be stratified for TB risk
Old healed TB on chest X-ray
Previously treated tuberculosis (option: those who have received previous  adequate treatment, should be monitored
regularly
– Prophylaxis protocol
      Options:
Isoniazid (INH), 300 mg/day for 9 or 6 months
Rifampicin, 600 mg/day for 4 months
Rifampicin, 10 mg/kg/day–Isoniazid 4 mg/kg/day for 3 months (increased hepatotoxicity)
– Treatment of TB associated with the use of TNF-alpha antagonist therapy
Anti-TB treatment (standard chemotherapy) according to the type of TB involvement.
Stop TNF-alpha antagonist therapy until TB treatment is finished
      (definitive suspension depends upon each individual case).
Adapted from references 29,31,32,40.
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(evidence based recommendation Class IV),
including the British Thoracic Society (40),
California County Health Department and
American Thoracic Society/CDC, United States
(31), as well as other important reviews (29,32).
The main recommendations are listed for the
prevention and treatment of those TB cases
associated with the use of TNF-alpha antagonist
therapy.
A rate of 11.8% and 2.4% of global and multidrug
resistant TB has been described recently in
Colombia, respectively (42). Therefore, health care
policies must ensure the best possible strategy
for the management and prevention of multidrug-
resistant TB in association with control campaigns
in low and middle income countries.
Concluding remarks
The introduction of TNF-alpha antagonist therapy
in Colombia with the concomitant appearance of
associated TB cases has set off the alarms about
what may be an increasing problem. One previous
case report has been made in Colombia, which
described a TB pulmonary reactivation case
related to infliximab therapy (43). Positive results
in TST greater than 40% (44) and the TB profile
denoted a situation consisting of a highly endemic
country with an incidence of 50/100,000, a
prevalence of 75/100,000 and mortality of 8.0
deaths/100,000/yr (45). This is associated with
the growing use of TNF-alpha antagonists therapy.
This therapy can increase the reactivation of a
latent condition and also a presentation of newly
active TB.
In high endemic areas of M tuberculosis infection
such as Peru (34), TST is not recommended for
the recognition of LTBI in patients with RA. This
is a policy that is recommended for application in
all highly endemic areas, including Colombia. As
shown in table 1, the usefulness of TST prior to
initiation of the TNF-alpha antagonist does not have
unanimous agreement among rheumatologists.
Other more sensitive diagnostic tests exist for the
identification of LTBI (QuantiFERON-TB Gold test,
T SPOT-TB). These are based upon detection of
interferon-gamma released by T-cells in response
to M. tuberculosis-specific antigens [early secre-
tory antigenic target 6 (ESAT-6) and culture fil-
trate protein-10 (CFP-10)]. However, they are not
yet routinely available and their validation awaits
confirmation in larger studies (46-48).
Clear guidelines are necessary as shown by case
reports from highly endemic areas. Formal
screening for latent infection is recommended for
patients who are candidates for TNF-alpha
antagonist therapy. This approach will detect the
clinical cases amongst the different presentation
forms, and will allow the selection of an appropriate
treatment of active and latent cases. The four
cases presented herein permitted the illustration
of the special characteristics and progression of
the agonist treatment problem. These will be useful
for encouraging health authorities and
rheumatology expert committees to delineate
policies for detecting and prevention of this serious
complications in cases treated with TNF-alpha
antagonists.
The Asociación Colombiana de Reumatología has
published recommendations to treat rheumatoid
arthritis (49,50) and spondiloartropathies (51) with
a short section focusing on the use of anti TNF
therapy in these pathologies. These recommen-
dations indicate that prior to the initiation of anti
TNF therapy, the TST and chest X Ray must be
done, and recommend the avoidance of anti TNF
treatment in the case of latent TB or active TB
infection. However, neither a clear discussion nor
mandate is implicit in these recommendations.
Concerning the rate of anti TNF therapy used in
Colombia, one report (52) indicates that
rheumatologists initiate anti-TNF therapy as
second line drug treatment in 16% of patients with
rheumatoid arthritis.
Subsequent to the submission of this manuscript,
two additional cases were observed (Rojas-
Villarraga A, Agudelo CA, Pineda-Tamayo R,
Porras A, Matute G, Anaya JM. Tuberculosis en
pacientes con enfermedades autoinmunes en
tratamiento con antagonistas del factor de
necrosis tumoral alfa. Resumen. Acta Med Colomb
2006;31(Suppl.):313), one under adalimubab
treatment for AS and another under etanercept
treatment for RA. However, because studies on
RA prevalence in Colombia or obligatory report of
TB cases in these patients have not been done,
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an objective calculation of ratio or likelihood of
being helped vs. harmed is precluded.
Finally, new developments are continuously oc-
curring in the field of biological therapy. The in-
creasing numbers of therapies for the modulation
of inflammatory response can bring the patients
enormous benefits; however, they can also gen-
erate problems that remain to be discovered.
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